VISION

VISION is an active learning platform that uses tumor, immune system and health data to predict the best treatment options.

How does VISION work?

  • Leveraging advanced analytics

utilizing the Agenus data repository to explore an immense range of drug-biology interactions not possible via traditional processes. This includes in silico modeling and AI.

  • Making predictions informed by laboratory experiments

that test how our drugs perform under conditions that mimic a patient’s tumor and immune system.

  • Getting the right drug to the right patient at the right time

designed to unlock the true potential of our broad immunotherapy portfolio.

The Agenus data repository comprises:

0 +
single cell profiles defining the immune stimulation response to anti-CTLA-4 therapy
Outcome: Biomarkers to accelerate development of botensilimab as monotherapy and in effective combinations
0 +
data points defining the life cycle of a T cell from activation to exhaustion, including the effects of anti-PD-1 therapy
Outcome: Accelerated clinical path for PD-1 combinations
0 +
unique peptides expressed on patient tumors across multiple cancer types

Outcome: Prioritized novel cancer therapeutic targets

0 +
proprietary immunotherapies evaluated across 10+ preclinical in vivo tumor models to gather pharmacodynamic data

Outcome: Bridges research hypotheses from the bench to the clinic

VISION Empowers